Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Genetic stability and recombinant product consistency

D Burstyn1, T Copmann, M Dinowitz

  • 1Biogen, Inc., Cambridge, MA.

Biologicals : Journal of the International Association of Biological Standardization
|June 1, 1993
PubMed
Summary

Industry scientists believe current methods adequately ensure recombinant product consistency. They argue against proposed cloning and sequencing measures, citing high costs and minimal benefits for regulatory and industry resources.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Canadian Surgery Forum.

Canadian journal of surgery. Journal canadien de chirurgie·2022
Same author

Effect of metritis on in-vitro uterine contractility in cows during the puerperium.

Animal reproduction science·2022
Same author

The effect of atorvastatin on haemostatic parameters in apparently healthy dogs.

The Journal of small animal practice·2019
Same author

Surgical process improvement tools: defining quality gaps and priority areas in gastrointestinal cancer surgery.

Current oncology (Toronto, Ont.)·2014
Same author

Taking immunogenicity assessment of therapeutic proteins to the next level.

Biologicals : journal of the International Association of Biological Standardization·2011
Same author

Basis for sample size in international conference on harmonization guidances.

Developments in biologicals·2006

Area of Science:

  • Biotechnology
  • Pharmaceutical Manufacturing
  • Regulatory Science

Background:

  • Recent proposals from Galibert and the Center for Biologics Evaluation and Research (CBER) suggest cloning and sequencing for ensuring recombinant product consistency.
  • A committee of U.S. industry scientists reviewed these suggestions.

Purpose of the Study:

  • To evaluate the efficacy and cost-effectiveness of proposed cloning and sequencing measures for assuring recombinant product consistency.
  • To present an alternative perspective on current capabilities for ensuring product consistency.

Main Methods:

  • Review of industry scientific committee findings.
  • Analysis of proposed regulatory suggestions regarding cloning and sequencing.
  • Assessment of current analytical and manufacturing technologies.

Related Experiment Videos

Main Results:

  • Disagreement with the proposed cloning and sequencing measures as a means to ensure product consistency.
  • Estimation of significant costs associated with regulatory agency review of artifactual errors and industry resource allocation.
  • Assertion that current technologies are sufficient for ensuring recombinant product consistency.

Conclusions:

  • The proposed cloning and sequencing measures are deemed unnecessary and overly costly.
  • Existing analytical and manufacturing technologies provide adequate assurance of recombinant product consistency.
  • Industry scientists advocate for the continued use of current technologies over the proposed regulatory changes.